Abstract
The ability to accumulate and retain the active metabolite of Ara-C varies widely among patients. Our studies demonstrate a significant correlation between clinical response and the pharmacokinetics of Ara-CTP in leukemia cells during therapy. Knowledge of the cellular pharmacology of Ara-CTP has been used to optimize dose rates and to design combination treatment schedules. An understanding of the cellular pharmacodynamics of other drugs is likely to be a useful parameter for planning treatment protocols.
Publication types
-
Research Support, U.S. Gov't, P.H.S.
-
Review
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Arabinofuranosylcytosine Triphosphate / metabolism*
-
Arabinonucleotides / metabolism*
-
Cytarabine / administration & dosage
-
Cytarabine / adverse effects
-
Cytarabine / pharmacokinetics*
-
Cytarabine / therapeutic use
-
Drug Evaluation
-
Humans
-
Leukemia / metabolism*
-
Leukemia / pathology
-
Leukemia, Myeloid, Acute / drug therapy
-
Leukemia, Myeloid, Acute / metabolism
-
Mitoxantrone / administration & dosage
-
Mitoxantrone / pharmacology
Substances
-
Arabinonucleotides
-
Cytarabine
-
Arabinofuranosylcytosine Triphosphate
-
Mitoxantrone